FAT10 protein is a recombinant protein produced in E. coli corresponding to the human sequence encompassing an N-terminal His6-tag within a leader sequence. FAT10, a ubiquitin-like protein, is encoded in the major histocompatibility complex class I locus and is synergistically inducible with interferon-gamma and tumor necrosis factor alpha. FAT10 expression causes apoptosis and it appears that FAT10 may modulate tumorigenesis through its interaction with the MAD2 spindle-assembly checkpoint protein. It has been demonstrated that FAT10 and its conjugates are rapidly degraded by the proteasome. Furthermore, a new interaction partner of FAT10, NEDD8 ultimate buster-1L (NUB1L), may function as a linker that targets FAT10 for degradation by the proteasome.
免疫原
GST-tagged recombinant protein corresponding to human FAT10.
アプリケーション
Anti-FAT10 Antibody, clone 4F1 is a highly specific mouse monoclonal antibody, that targets FAT10 & has been tested in western blotting, IP & ICC.
Immunocytochemistry Analysis: A representative lot detected FAT10 in HA-FAT10 transfected HEK293 cells (Aichem, A., et al. (2010). Nature Commun. 1:13). Immunoprecipitation Analysis: A representative lot immunoprecipitated FAT10 in transfected HA-FAT10 HEK293 cells cultivated with IFNgamma and TNFalpha (Aichem, A., et al. (2010). Nature Commun. 1:13).
品質
Evaluated by Western Blotting in HepG2 cell lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected FAT10 in 10 µg of HepG2 cell lysate.
ターゲットの説明
~18 kDa observed. FAT10 FAT10ylates itself as well as other proteins so additional bands may be observed due to the FAT10ylation of endogenous proteins (Aichem, A., et al. (2010). Nature Commun. 1:13.),(Aichem, A., et al. J Cell Sci. (2012)125:4576-85).
物理的形状
Format: Purified
その他情報
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
American journal of cancer research, 14(4), 1523-1544 (2024-05-10)
Although sorafenib is the first-line therapeutic agent for advanced hepatocellular carcinoma (HCC), the development of drug resistance in HCC cells limits its clinical efficacy. However, the key factors involved in mediating the sorafenib resistance of HCC cells and the underlying